English  |  正體中文  |  简体中文  |  2818744  
???header.visitor??? :  28298853    ???header.onlineuser??? :  569
???header.sponsordeclaration???
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
???ui.leftmenu.abouttair???

???ui.leftmenu.bartitle???

???index.news???

???ui.leftmenu.copyrighttitle???

???ui.leftmenu.link???

"lanzalone s"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1??? ???jsp.browse.items-by-author.order2???

Showing items 1-6 of 6  (1 Page(s) Totally)
1 
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2021-09-01T01:54:20Z Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study Faivre S.; Raymond E.; Boucher E.; Douillard J.; Lim H.Y.; Kim J.S.; Zappa M.; Lanzalone S.; Lin X.; DePrimo S.; Harmon C.; Ruiz-Garcia A.; Lechuga M.J.; ANN-LII CHENG
臺大學術典藏 2021-09-01T01:54:07Z Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib Harmon C.S.; DePrimo S.E.; Raymond E.; ANN-LII CHENG; Boucher E.; Douillard J.-Y.; Lim H.Y.; Kim J.S.; Lechuga M.J.; Lanzalone S.; Lin X.; Faivre S.
臺大學術典藏 2021-09-01T01:54:07Z Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib Faivre S.; Zappa M.; Vilgrain V.; Boucher E.; Douillard J.-Y.; Lim H.Y.; Kim J.S.; Im S.-A.; Kang Y.-K.; Bouattour M.; Dokmak S.; Dreyer C.; Sablin M.-P.; Serrate C.; ANN-LII CHENG; Lanzalone S.; Lin X.; Lechuga M.J.; Raymond E.
臺大學術典藏 2021-09-01T01:53:43Z Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial ANN-LII CHENG; Kang Y.-K.; Lin D.-Y.; Park J.-W.; Kudo M.; Qin S.; Chung H.-C.; Song X.; Xu J.; Poggi G.; Omata M.; Lowenthal S.P.; Lanzalone S.; Yang L.; Lechuga M.J.; Raymond E.
臺大學術典藏 2020-12-02T02:33:14Z Final results of the large-scale multinational trial PROFILE 1005: Efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer Blackhall F.; Ross Camidge D.; Shaw A.T.; Soria J.-C.; Solomon B.J.; Mok T.; Hirsh V.; J?Nne P.A.; Shi Y.; Pan-Chyr Yang; De Pas T.; Hida T.; De Castro Carpe?O J.; Lanzalone S.; Polli A.; Iyer S.; Reisman A.; Wilner K.D.; Kim D.-W.; Blackhall F.; PAN-CHYR YANG et al.
國立臺灣大學 2012 UPDATED RESULTS OF A GLOBAL PHASE II STUDY WITH CRIZOTINIB IN ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) Kim, D.; Ahn, M.; Yang, P.; Liu, X.; De Pas, T.; Crino, L.; Lanzalone, S.; Polli, A.; Shaw, A.

Showing items 1-6 of 6  (1 Page(s) Totally)
1 
View [10|25|50] records per page